KBIO Stock UPDATES Kalobios Pharmaceuticals Inc (KBIO) 1.84 10/22/2014

New Post Public Reply Private Reply Replies (0) Message Board

Oct 22, 2014 at 1:42 PM

Kalobios Pharmaceuticals Inc (KBIO) 1.84 $KBIO

Cerulean Pharma (CERU) Worth Watching: Stock Soars 30.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 8:25AM CDT
Cerulean Pharma (CERU) was a big mover last session, with shares surging nearly 31% on the day.
MNK: 87.59 (-1.71), KBIO: 1.84 (+0.02), AKRX: 41.60 (+0.31), CERU: 4.30 (unch)

Publication by KaloBios and Collaborators Shows EphA3 as Target for Highly Selective Anticancer Therapy
PR Newswire - Thu Aug 14, 7:00AM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the publication of preclinical findings describing EphA3 as a novel target expressed by a broad range of human tumors, and whose activation can lead to the selective disruption of the tumor microenvironment and newly formed tumor blood vessels. The expression and function of EphA3 in the tumor microenvironment but not in adult normal tissues together with the favorable safety profile as observed thus far in a Phase 1-2 clinical study, where infusion reactions have been the most common adverse event, supports the development of KB004 (KaloBios' Humaneered® anti-EphA3 monoclonal antibody [mAb]) as a potential treatment for both hematologic and solid tumors.
KBIO: 1.84 (+0.02)

KaloBios (KBIO) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 9:04AM CDT
KaloBios (KBIO) Enters Oversold Territory
KBIO: 1.84 (+0.02)

Relypsa (RLYP) Worth Watching: Stock Gains 13.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 8:46AM CDT
Relypsa (RLYP) was a big mover last session, with shares rising over 13% on the day.
MNK: 87.56 (-1.74), KBIO: 1.84 (+0.02), AKRX: 41.60 (+0.31), RLYP: 18.70 (-0.07)

KaloBios Provides Clinical Update and Reports Second Quarter Financial Results
PR Newswire - Thu Aug 07, 7:00AM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on its current clinical programs and announced financial results for the second quarter of 2014.
KBIO: 1.84 (+0.02)

KaloBios Provides Update on KB001-A Partnership and Clinical Status
PR Newswire - Mon Jul 28, 3:01PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on the status of the KB001-A development program, including an update on its KB001-A collaboration with Sanofi Pasteur.
KBIO: 1.84 (+0.02)

Cutera, Inc. (CUTR) in Focus: Stock Adds 7.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 8:11AM CDT
Cutera, Inc. (CUTR) was a big mover last session, as the company saw its shares rise over 7% on the day.
KBIO: 1.84 (+0.02), AKRX: 41.60 (+0.31), AERI: 22.33 (+0.58), CUTR: 9.76 (-0.16)

5 Stocks Under $10 Setting Up to Soar
at The Street - Thu Jun 26, 12:56PM CDT
These under-$10 stocks look poised to break out and trade higher from current levels.
HEAR: 5.62 (-0.20), NWBO: 4.74 (-0.35), KBIO: 1.84 (+0.02), SFUN: 10.35 (-0.25), ONTX: 4.25 (-0.28), PRAN: 1.95 (-0.02)

3 Health Care Stocks Under $10 to Trade for Breakouts
at The Street - Wed Jun 25, 7:34AM CDT
These under-$10 health care stocks are within range of triggering breakout trades.
AVNR: 11.74 (-0.05), KBIO: 1.84 (+0.02), CCM: 7.62 (+0.18)

Akorn (AKRX) in Focus: Stock Moves 5.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 8:18AM CDT
Akorn, Inc. (AKRX) was a big mover last session, as the company saw its shares rise by almost 6% on the day.
CPXX: 1.85 (+0.05), MNK: 87.56 (-1.74), KBIO: 1.84 (+0.02), AKRX: 41.60 (+0.31)

Aquinox Pharmaceuticals (AQXP) in Focus: Stock Plunges 15.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 8:00AM CDT
Aquinox Pharmaceuticals has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the last day
MNK: 87.56 (-1.74), KBIO: 1.84 (+0.02), AQXP: 7.41 (-0.01), AKRX: 41.60 (+0.31)

Acasti Pharma Inc (ACST) Jumps: Stock Rises 7.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 7:30AM CDT
Acasti Pharma Inc. (ACST) was a big mover last session, as its shares rose over 7% on the day.
MNK: 87.56 (-1.74), ACST: 0.53 (-0.03), KBIO: 1.84 (+0.02), AKRX: 41.60 (+0.31)

Will KaloBios (KBIO) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 9:22AM CDT
Will KaloBios (KBIO) Continue to Surge Higher?
KBIO: 1.84 (+0.02)

Where are They Now? Biotech IPO Class of 2013, March Edition
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
This year you can't squeeze a pipette without hitting another biotech offering. The red-hot sector has seen more than 25 IPOs so far this year. Many are doubling and tripling in price in their first days of trading. In a frenzied market like this...
TTPH: 23.66 (-0.23), KBIO: 1.84 (+0.02), SNY: 52.68 (+0.53), STML: 12.49 (-0.36)

How KaloBios (KBIO) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:33AM CDT
KaloBios is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. It currently has a Zacks Industry Rank of 9 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.
KBIO: 1.84 (+0.02)

KaloBios Announces Fiscal Year 2013 Financial Results
PR Newswire - Thu Mar 13, 3:01PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on corporate accomplishments in fiscal 2013 and key milestones for 2014 as well as announcing financial results for fiscal year 2013.
KBIO: 1.84 (+0.02)

KaloBios Announces Upcoming Participation at ROTH and BioCentury's Future Leaders in the Biotech Industry Conferences
PR Newswire - Mon Mar 10, 3:01PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following upcoming investor conferences:
KBIO: 1.84 (+0.02)

Envestnet President Bill Crager To Chair Panel At ABA Wealth Management And Trust Conference
PR Newswire - Wed Feb 26, 7:45AM CST
Envestnet, Inc. (NYSE: ENV), a leading provider of integrated wealth management technology and services to investment advisors and wealth managers, announces that President Bill Crager will moderate a panel discussion at the American Bankers Association (ABA) Wealth Management and Trust Conference, which will take place from February 26-28, 2014 at the Hilton San Diego Bayfront Hotel.
KBIO: 1.84 (+0.02), ENV: 41.01 (-0.78)

InMobi Partners with Top Football News Publisher, Adversport's Foot Mercato
PR Newswire - Wed Feb 26, 7:17AM CST
InMobi, the world's largest independent mobile advertising company, today announced an exclusive partnership agreement with Adversport, the publisher of Foot Mercato, the leading football app on the App Store. InMobi has been selected as the exclusive mobile advertising platform for Adversport's mobile and tablet properties across France (Foot Mercato), Germany (Fussballtransfer) and Spain (Fichajes).
KBIO: 1.84 (+0.02)

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech - 2014 Edition
M2 - Mon Feb 17, 9:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/h484j7/discovery_stage) has announced the addition of the "Discovery Stage Partnering Terms and Agreements in Pharma and Biotech" report to their offering. This report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 4,000 links to online copies of actual discovery stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of discovery stage deal making and business activities. Companies Mentioned: - Abbott - Actavis - Bristol-Myers Squibb - Celgene - Daiichi Sankyo - Elan - Eli Lilly - Fresenius Biotech - GE Healthcare - GlycArt - ImmunoGen - Intrexon - Johnson & Johnson - KaloBios Pharmaceuticals - Lpath - Lundbeck - Macrogenics - Merck & Co - Novo Nordisk - Orbimed Advisors - Peregrine Pharmaceuticals - Pfizer - RIT Oncology - Seattle Genetics - TrovaGene - TTFactor - University of Texas - Wyeth - Xencor - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/h4...very_stage About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
JNJ: 101.16 (+0.80), NVO: 45.60 (+0.17), KBIO: 1.84 (+0.02), MRK: 55.22 (+0.09), LLY: 64.67 (-0.01), BMY: 51.93 (-0.02), CELGZ: 3.52 (-0.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HANGCHA's AI-Fork Revolution: Bold Steps to 2030

Forklifts and the Future: A Fork in the Road for HANGCHA There's a movement happening, folks, and I don't mean in the usual stock ticker shift way. We're talking forklifts here—AI-powered, no less. HANGCHA Group, a name that may or may not roll off the tongue but sure makes waves in manufacturing, just held its 4th Global Dealers Conference in Hangzhou, China. If you're...

CGI Shines with Strong Q4, Announces Dividend Hike

CGI Records Impressive Fourth Quarter Growth Well, CGI's got reason to strut its stuff this time around. Clocked in with a fourth-quarter revenue of $4.15 billion - that's a nice 3.3% bump up year-over-year, if you leave the currency noise out of it, it's about 2.5%. The real kicker? Net earnings shot up 20.8%. In a world where everyone’s fighting over scraps, these...

Replit Wins 2026 Microsoft Startup Partner Award

Replit's Triumph in the Microsoft Ecosystem If there's one thing you come to expect from this dizzying dance of technology and business, it's that standout players get their due when they push the envelope. Replit just snagged a gleaming accolade by being named Microsoft's 2026 Partner of the Year for Startups. That's a hefty badge, especially coming from a giant like...

Oracle's Opower Drives Record Utility Success in 2026

Peak Performance: Oracle Opower's Latest Surge Hey, energy watchers, if you don't have Oracle Opower on your radar, it might be time for a check-up! These folks have achieved more peak energy demand reduction this year than you've seen in quite some time. We're talking 1 gigawatt reduced across 70-plus events, no less. Wrap your head around that for a minute! That's like...

Lake Victoria Gold Kicks Off Imwelo Drilling Program

Drill Bit Meets Tanzanian Rock: Lake Victoria's Next Move It's not every day you hear about a company plunging rotary bits into African soil with as much gusto as Lake Victoria Gold, eh? The folks over at LVG have decided it's time to hit the ground—or rather, dig into it—with an ambitious 6,500-meter grade control drilling program at their Imwelo Gold Project in...

Group 1 Expands with Porsche Atlanta Northwest Acquisition

Porsche Atlanta Northwest Joins Group 1 Automotive This ain't just some humdrum industry announcement, folks. Group 1 Automotive, the Houston-based heavyweight, has tightened its grip on the Atlanta car scene by welcoming Porsche Atlanta Northwest into the fold. This development marks the latest notch in Group 1’s belt as they continue gobbling up Atlanta-area...

Virginia Water Alerts: Serving 384K with Flow Tips

Keeping Water Flowing Smoothly in Virginia Water's one of those things you hardly notice until it's not there—or worse, when it throws a wrench in your usual routine. Virginia American Water, a branch of the big-dog utility American Water (NYSE: AWK), is trying its darndest to keep folks from missing a beat. They offer up some sage advice on staying plugged into the...

Webull Faces Class Action Over China Ties Missteps

What's Brewing with Webull? Troubling allegations have bubbled to the surface regarding Webull Corporation, now in the crosshairs of a securities class action. The heart of this legal storm is the claim that Webull, under the ticker NASDAQ:BULL, allegedly disguised its deep-seated ties with China. And boy, when those revelations hit the news on October 7, 2026, it sent...

PHFA Unveils 2027/2028 Plan for Housing Tax Credits

Fresh Blueprint for Affordable Housing in Pennsylvania Alright, folks, it's time we talk about something other than Wall Street hype: the nitty-gritty of housing, but not just any housing. I'm talking about low-income housing and what Pennsylvania's Housing Finance Agency (PHFA) has cooked up for us. They’ve released their much-anticipated 2027/2028 Qualified Allocation...

Vipboss Offers Big Black Friday Deals for Adventurers

Anticipating Next Year’s Adventures Today Outdoor enthusiasts, listen up! Just because the frost is nipping at your nose doesn’t mean you can’t start dreaming about where the open road or sea will take you next. Vipboss, a known figure in the world of reliable power solutions, is rolling out a Black Friday bonanza, ready to electrify your preparation game with...